ALKS vs. TARS
ALKS (Alkermes plc) and TARS (Tarsus Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ALKS returned 13.13%/yr vs 11.64%/yr for TARS. At a 0.24 correlation, their price movements are largely independent.
Performance
ALKS vs. TARS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALKS achieves a 52.82% return, which is significantly higher than TARS's -28.24% return.
ALKS
- 1D
- 3.48%
- 1M
- 25.14%
- YTD
- 52.82%
- 6M
- 44.80%
- 1Y
- 36.74%
- 3Y*
- 13.16%
- 5Y*
- 13.13%
- 10Y*
- -0.52%
TARS
- 1D
- 2.35%
- 1M
- -9.00%
- YTD
- -28.24%
- 6M
- -28.24%
- 1Y
- 33.82%
- 3Y*
- 51.02%
- 5Y*
- 11.64%
- 10Y*
- —
ALKS vs. TARS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ALKS Alkermes plc | 52.82% | -2.71% | 3.68% | 6.16% | 12.34% | 16.59% | 16.46% |
TARS Tarsus Pharmaceuticals, Inc. | -28.24% | 47.88% | 173.43% | 38.13% | -34.84% | -45.56% | 100.83% |
Correlation
The correlation between ALKS and TARS is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2020 | 0.24 |
Fundamentals
ALKS:
$7.11B
TARS:
$2.52B
ALKS:
$0.91
TARS:
-$1.13
ALKS:
4.60
TARS:
4.69
ALKS:
4.06
TARS:
7.23
ALKS:
$1.56B
TARS:
$535.08M
ALKS:
$1.02B
TARS:
$483.93M
ALKS:
$249.70M
TARS:
-$39.55M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALKS vs. TARS — Risk / Return Rank
ALKS
TARS
ALKS vs. TARS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Alkermes plc (ALKS) and Tarsus Pharmaceuticals, Inc. (TARS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ALKS | TARS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.14 | ||
| Sortino ratioReturn per unit of downside risk | +0.09 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.17 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.66 | 1.12 | +0.55 |
| Martin ratioReturn relative to average drawdown | 3.50 | 2.57 | +0.92 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ALKS | TARS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.91 | 0.77 | +0.14 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.35 | 0.20 | +0.16 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.01 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.32 | -0.22 |
Drawdowns
ALKS vs. TARS - Drawdown Comparison
The maximum ALKS drawdown since its inception was -96.14%, which is greater than TARS's maximum drawdown of -77.67%. Use the drawdown chart below to compare losses from any high point for ALKS and TARS.
Loading charts...
Drawdown Indicators
| ALKS | TARS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.14% | -77.67% | -18.47% |
Max Drawdown (1Y)Largest decline over 1 year | -22.20% | -30.42% | +8.22% |
Max Drawdown (3Y)Largest decline over 3 years | -31.58% | -47.28% | +15.70% |
Max Drawdown (5Y)Largest decline over 5 years | -33.18% | -71.29% | +38.11% |
Max Drawdown (10Y)Largest decline over 10 years | -80.58% | — | — |
Current DrawdownCurrent decline from peak | -56.39% | -28.78% | -27.61% |
Average DrawdownAverage peak-to-trough decline | -67.25% | -40.62% | -26.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.54% | 13.18% | -2.64% |
Volatility
ALKS vs. TARS - Volatility Comparison
Alkermes plc (ALKS) and Tarsus Pharmaceuticals, Inc. (TARS) have volatilities of 13.20% and 13.29%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALKS | TARS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.20% | 13.29% | -0.09% |
Volatility (6M)Calculated over the trailing 6-month period | 30.12% | 28.45% | +1.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.64% | 44.27% | -3.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 37.32% | 59.12% | -21.80% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.29% | 63.95% | -22.66% |
Dividends
ALKS vs. TARS - Dividend Comparison
Neither ALKS nor TARS has paid dividends to shareholders.
Financials
ALKS vs. TARS - Financials Comparison
This section allows you to compare key financial metrics between Alkermes plc and Tarsus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALKS vs. TARS - Profitability Comparison
ALKS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a gross profit of 0.00 and revenue of 392.91M. Therefore, the gross margin over that period was 0.0%.
TARS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported a gross profit of 152.66M and revenue of 162.05M. Therefore, the gross margin over that period was 94.2%.
ALKS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported an operating income of -48.28M and revenue of 392.91M, resulting in an operating margin of -12.3%.
TARS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported an operating income of -6.12M and revenue of 162.05M, resulting in an operating margin of -3.8%.
ALKS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a net income of -66.48M and revenue of 392.91M, resulting in a net margin of -16.9%.
TARS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported a net income of -6.97M and revenue of 162.05M, resulting in a net margin of -4.3%.
Frequently Asked Questions
ALKS and TARS have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TARS has higher volatility (13.29%) compared to ALKS (13.20%). In terms of maximum drawdown, ALKS dropped -96.14% vs TARS's -77.67%.
ALKS currently has the higher Sharpe Ratio (0.91 vs 0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALKS and TARS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer